Last edition
News about
TuHURA Biosciences Files IND for TBS-2025 in Relapsed/Refractory mutNPM1 AML
TuHURA Biosciences has filed an IND with the FDA to evaluate its VISTA-targeting antibody TBS-2025 in combination with a menin inhibitor for relapsed/refractory mutNPM1 AML.
GRAIL Reports Topline Results from NHS-Galleri Trial of Multi-Cancer Early Detection Test
Results from the NHS-Galleri trial show that annual multi-cancer screening with the Galleri test reduced Stage IV diagnoses and significantly increased early cancer detection across England’s NHS population.
Hansa Biopharma's Imlifidase BLA Accepted by US FDA for Priority Review
FDA accepts Hansa Biopharma’s BLA for imlifidase, supported by strong Phase III ConfIdeS data demonstrating significant kidney function improvement in highly sensitized transplant patients.
Johnson & Johnson to Invest Over $1 Billion in Pennsylvania Cell Therapy Manufacturing Facility
Johnson & Johnson (JNJ) has announced an investment of more than $1 billion to build a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania.
Merck and Mayo Clinic Partner to Accelerate AI-Driven Drug Discovery and Development
Merck, known as MSD outside the United States and Canada, has entered into a strategic research and development agreement with Mayo Clinic, one of the world’s leading hospital systems, to advance the use of artificial intelligence (AI), advanced analytics and multimodal clinical data in drug discovery and development.
BioNTech files patent lawsuit against Moderna over COVID-19 vaccine technology
German biotechnology firm BioNTech has filed a patent infringement lawsuit against U.S.-based vaccine maker Moderna in a federal court in Delaware. The case centers on Moderna’s updated COVID-19 vaccine, mNEXSPIKE, which BioNTech claims uses technology protected under its patents.
Novartis' Remibrutinib Shows Positive Phase III Results in Chronic Inducible Urticaria
Pivotal RemIND trial meets primary endpoint across three major CIndU subtypes, positioning oral remibrutinib as a potential first targeted therapy for inducible chronic hives.
India Ratings and Research (Ind-Ra) has retained a neutral outlook on India’s pharmaceutical sector for FY27, projecting revenue growth of around 10 percent year on year. The growth is expected to be driven by sustained domestic demand and rising momentum in the contract development and manufacturing organisation segment.
GSK Reports Real-World Data Showing Strong Effectiveness of RSV Vaccine in Older Adults
New US and Denmark studies presented at ReSViNET 2026 show GSK’s RSV vaccine is associated with reduced hospitalisations and lower risk of severe cardiovascular and respiratory complications in adults aged 60 and above.
FDA Issues Complete Response Letter for Disc Medicine's Bitopertin in Rare Blood Disorder
US regulator seeks Phase III APOLLO trial results before approving bitopertin for erythropoietic protoporphyria, pushing potential decision until mid-2027.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy